Abstract
Purpose of review
Describe most recent data on manifestations and treatment of intestinal and extra-intestinal manifestations of Campylobacter among immunocompromised patients.
Recent findings
Resistance to fluoroquinolones, macrolides, and tetracycline challenge traditional empiric therapies.
Summary
Recurrent Campylobacter enteritis and bacteremia are associated with hypogammaglobinemia, HIV, transplant-associated immunotherapy, and hematologic malignancies. C. jejuni and C. coli are the most commonly associated Campylobacter species although C. fetus, C. upsaliensis, C. lari, C. curvus, and C. rectus should be considered as potential causative agents of rare extra-intestinal infections. Successful diagnosis and treatment of these cases may require the recognition of the limits of standard diagnostics and the recent emergence of highly resistant strains of Campylobacter, particularly C. coli.
No comments:
Post a Comment